Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome.
amiloride
diuretic
edema
furosemide
hydrochlorothiazide
intravenous
nephrotic syndrome
oral
resistant
weight
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
11
10
2023
revised:
30
10
2023
accepted:
01
11
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Data on diuretic treatment in nephrotic syndrome (NS) are scarce. Our goal was to assess the non-inferiority of the combined oral diuretics (furosemide/hydrochlorothiazide/amiloride) compared to intravenous (i.v.) furosemide in patients with NS and resistant edema. We conducted a prospective randomized trial on 22 patients with resistant nephrotic edema (RNE), defined as hypervolemia and a FENa < 0.2%. Based on a computer-generated 1:1 randomization, we assigned patients to receive either intravenous furosemide (40 mg bolus and then continuous administration of 5 mg/h) or oral furosemide (40 mg/day) and hydrochlorothiazide/amiloride (50/5 mg/day) for a period of 5 days. Clinical and laboratory measurements were performed daily. Hydration status was assessed by bioimpedance on day 1 and at the end of day 5 after treatment initiation. The primary endpoint was weight change from baseline to day 5. Secondary endpoints were hydration status change measured by bioimpedance and safety outcomes (low blood pressure, severe electrolyte disturbances, acute kidney injury and worsening hypervolemia). Primary endpoint analysis showed that after 5 days of treatment, there was a significant difference in weight change from baseline between groups [adjusted mean difference: -3.33 kg (95% CI: -6.34 to -0.31), A combination of oral diuretics based on furosemide, amiloride and hydrochlorothiazide is non-inferior to i.v. furosemide in weight control of patients with RNE and a similar safety profile.
Sections du résumé
BACKGROUND
BACKGROUND
Data on diuretic treatment in nephrotic syndrome (NS) are scarce. Our goal was to assess the non-inferiority of the combined oral diuretics (furosemide/hydrochlorothiazide/amiloride) compared to intravenous (i.v.) furosemide in patients with NS and resistant edema.
METHODS
METHODS
We conducted a prospective randomized trial on 22 patients with resistant nephrotic edema (RNE), defined as hypervolemia and a FENa < 0.2%. Based on a computer-generated 1:1 randomization, we assigned patients to receive either intravenous furosemide (40 mg bolus and then continuous administration of 5 mg/h) or oral furosemide (40 mg/day) and hydrochlorothiazide/amiloride (50/5 mg/day) for a period of 5 days. Clinical and laboratory measurements were performed daily. Hydration status was assessed by bioimpedance on day 1 and at the end of day 5 after treatment initiation. The primary endpoint was weight change from baseline to day 5. Secondary endpoints were hydration status change measured by bioimpedance and safety outcomes (low blood pressure, severe electrolyte disturbances, acute kidney injury and worsening hypervolemia).
RESULTS
RESULTS
Primary endpoint analysis showed that after 5 days of treatment, there was a significant difference in weight change from baseline between groups [adjusted mean difference: -3.33 kg (95% CI: -6.34 to -0.31),
CONCLUSIONS
CONCLUSIONS
A combination of oral diuretics based on furosemide, amiloride and hydrochlorothiazide is non-inferior to i.v. furosemide in weight control of patients with RNE and a similar safety profile.
Identifiants
pubmed: 37959360
pii: jcm12216895
doi: 10.3390/jcm12216895
pmc: PMC10648037
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Kidney Int. 1994 Jan;45(1):266-81
pubmed: 8127018
Eur J Heart Fail. 2019 Nov;21(11):1415-1422
pubmed: 31074184
Clin Ter. 1984 Apr 15;109(1):23-9
pubmed: 6233076
Hypertension. 2012 Nov;60(5):1346-51
pubmed: 22987920
Kidney Int Rep. 2017 Sep;2(5):893-904
pubmed: 28890943
Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F429-30
pubmed: 26084931
J Am Soc Nephrol. 2005 Dec;16(12):3642-50
pubmed: 16267158
BMC Nephrol. 2022 Sep 20;23(1):316
pubmed: 36127661
J Am Soc Nephrol. 2002 May;13(5):1131-5
pubmed: 11960999
Nephrol Dial Transplant. 2015 May;30(5):781-9
pubmed: 25609736
Front Pediatr. 2016 Jan 11;3:111
pubmed: 26793696
Hypertension. 2016 Jan;67(1):197-205
pubmed: 26628676
N Engl J Med. 2017 Nov 16;377(20):1964-1975
pubmed: 29141174
Physiol Rep. 2018 Sep;6(17):e13835
pubmed: 30178569
Nephron. 1984;37(1):43-8
pubmed: 6371561
J Clin Invest. 1983 Jan;71(1):91-103
pubmed: 6848563
Indian J Pediatr. 2020 Aug;87(8):633-640
pubmed: 32232733
Clin J Am Soc Nephrol. 2016 May 6;11(5):761-769
pubmed: 26933188
Clin Drug Investig. 2017 Dec;37(12):1175-1181
pubmed: 28965280
Am J Kidney Dis. 2017 Mar;69(3):420-427
pubmed: 28043731
Am J Physiol Renal Physiol. 2006 Jul;291(1):F208-17
pubmed: 16403831
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1248-1257
pubmed: 30936153
Am J Nephrol. 1998;18(3):251-5
pubmed: 9627045
Clin Exp Pharmacol Physiol. 1975 Jul-Aug;2(4):277-87
pubmed: 1097143
Am J Nephrol. 1990;10(1):44-8
pubmed: 2188506
Pediatr Nephrol. 2013 Aug;28(8):1153-6
pubmed: 23529637
J Am Soc Nephrol. 2001 Mar;12(3):598-601
pubmed: 11181809
J Hypertens. 2016 Aug;34(8):1621-9
pubmed: 27214087
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Physiol Rep. 2018 Jun;6(12):e13743
pubmed: 29939487
Int J Nephrol. 2015;2015:975934
pubmed: 26294976
Ann Intern Med. 1979 Nov;91(5):688-96
pubmed: 496101
J Am Coll Cardiol. 2010 Nov 2;56(19):1527-34
pubmed: 21029871
Pediatr Nephrol. 2007 Dec;22(12):1983-90
pubmed: 17554565
J Hypertens. 2014 Aug;32(8):1672-7; discussion 1677
pubmed: 24805959
Am J Kidney Dis. 2017 Jan;69(1):136-142
pubmed: 27814935
Front Physiol. 2019 Jan 15;9:1868
pubmed: 30697163
Blood. 2012 Oct 18;120(16):3206-13
pubmed: 22948045